Enzene Launches NeX™ to Slash Biomanufacturing Costs and Boost Local Access to Biologics

#BioManufacturing #EnzeneBiosciences #Nex #Biologics #ContinuousManufacturing #HealthEquity #BiotechInnovation #PharmaSupplyChain #Biosimilars #HealthcareAccess

"A conventional biologics plant often requires between $300 million and $400 million to build. With our fully-connected continuous manufacturing platform, the same output can be achieved for $60-$80 million. The efficiency comes from a compact, integrated system architecture rather than the scale-intensive layouts of fed-batch facilities, allowing for long-term cost advantage and high product yields for locally manufactured biomedicines.” - Dr. Himanshu Gadgil, CEO - Enzene

August 2026 : Biologics are revolutionizing modern medicine, but building the facilities to produce them has historically required staggering amounts of capital and time. Global Continuously Innovative Development and Manufacturing Organization (CIDMO™) Enzene is changing that reality with the launch of NeX™ - a comprehensive, turnkey partnership model designed to make world-class biomanufacturing accessible anywhere on the globe.

NeX™ allows governments, academic institutions, and biopharma companies to build high-yielding, local biomanufacturing capabilities without the crushing financial burden of traditional setups. Powered by Enzene’s proven EnzeneX® Fully-Connected Continuous Manufacturing™ (FCCM™) platform, the program moves production closer to patients and supply chains, drastically expanding affordability for life-saving therapeutics.

The NeX™ package offers end-to-end support, including facility design, technology transfer, IP licensing, and workforce training via Enzene's SparX™ curriculum. In select regions, partners can also access Enzene’s biosimilar portfolio to manufacture locally. Remarkably, facilities built under this framework are estimated to reach commercial readiness in under three years.

Commenting on the launch, Dr. Himanshu Gadgil, CEO of Enzene, highlighted the dramatic economic advantage: "A conventional biologics plant often requires between $300 million and $400 million to build. With our fully-connected continuous manufacturing platform, the same output can be achieved for $60-$80 million. The efficiency comes from a compact, integrated system architecture rather than the scale-intensive layouts of fed-batch facilities, allowing for long-term cost advantage and high product yields for locally manufactured biomedicines. We are already engaged in discussions with multiple governments and corporations all around the world and are looking forward to helping deliver affordable medicines to patients worldwide."

By slashing capital requirements and streamlining localized supply chains, Enzene isn't just offering a technology platform - it's creating a blueprint for global health equity.

Pro MFG Media Newsletter

Get regular manufacturing insights that matter and enable business.